Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial

REFERENCES

1. 1.↵
   1. Visvanathan S,
   2. Rahman MU,
   3. Keystone E,
   4. Genovese M,
   5. Klareskog L,
   6. Hsia E,
   7. et al.

   Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Daien CI,
   2. Fabre S,
   3. Rittore C,
   4. Soler S,
   5. Daien V,
   6. Tejedor G,
   7. et al.

   TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 2012;79:471–5.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Klimiuk PA,
   2. Sierakowski S,
   3. Domyslawska I,
   4. Chwiecko J

   . Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 2004;31:238–42.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Padyukov L,
   2. Lampa J,
   3. Heimburger M,
   4. Ernestam S,
   5. Cederholm T,
   6. Lundkvist I,
   7. et al.

   Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Curtis JR,
   2. Luijtens K,
   3. Kavanaugh A

   . Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res 2012;65:658–67.

   OpenUrl
6. 6.↵
   1. Curtis JR,
   2. Yang S,
   3. Chen L,
   4. Park GS,
   5. Bitman B,
   6. Wang B,
   7. et al.

   Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 2012;71:206–12.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Keystone EC,
   2. Curtis JR,
   3. Fleischmann RM,
   4. Furst DE,
   5. Khanna D,
   6. Smolen JS,
   7. et al.

   Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol 2011;38:990–6.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. van der Heijde D,
   2. Keystone EC,
   3. Curtis JR,
   4. Landewe RB,
   5. Schiff MH,
   6. Khanna D,
   7. et al.

   Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012;39:1326–33.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Moreland LW,
   2. O’Dell JR,
   3. Paulus HE,
   4. Curtis JR,
   5. Bathon JM,
   6. St Clair EW,
   7. et al.

   A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012;64:2824–35.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Klaasen R,
    2. Wijbrandts CA,
    3. Gerlag DM,
    4. Tak PP

    . Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011;63:359–64.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Maska LB,
    2. Sayles HR,
    3. O’Dell JR,
    4. Curtis JR,
    5. Bridges SL Jr.,
    6. Moreland LW,
    7. et al.

    Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res 2012;64:1804–10.

    OpenUrlCrossRef
12. 12.↵
    1. Hosmer DW,
    2. Lemeshow S

    . Applied logistic regression. 2nd edition. Hoboken, NJ: John Wiley and Sons; 2000.
13. 13.↵
    1. Lemeshow S,
    2. Hosmer DW

    . A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92–106.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Curtis JR,
    2. van der Helm-van Mil AH,
    3. Knevel R,
    4. Huizinga TW,
    5. Haney DJ,
    6. Shen Y,
    7. et al.

    Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:1794–803.

    OpenUrlCrossRef
15. 15.↵
    1. Hyrich KL,
    2. Watson KD,
    3. Silman AJ,
    4. Symmons DP

    . Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558–65.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Anderson JJ,
    2. Wells G,
    3. Verhoeven AC,
    4. Felson DT

    . Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22–9.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Saevarsdottir S,
    2. Wallin H,
    3. Seddighzadeh M,
    4. Ernestam S,
    5. Geborek P,
    6. Petersson IF,
    7. et al.

    Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011;70:469–75.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Rezaei H,
    2. Saevarsdottir S,
    3. Forslind K,
    4. Albertsson K,
    5. Wallin H,
    6. Bratt J,
    7. et al.

    In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 2012;71:186–91.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Aletaha D,
    2. Funovits J,
    3. Keystone EC,
    4. Smolen JS

    . Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226–35.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Verstappen SM,
    2. van Albada-Kuipers GA,
    3. Bijlsma JW,
    4. Blaauw AA,
    5. Schenk Y,
    6. Haanen HC,
    7. et al.

    A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38–43.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Gulfe A,
    2. Kristensen LE,
    3. Geborek P

    . Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517–21.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Bakker MF,
    2. Jacobs JW,
    3. Welsing PM,
    4. Vreugdenhil SA,
    5. van Booma-Frankfort C,
    6. Linn-Rasker SP,
    7. et al.

    Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70:1099–103.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Ma MH,
    2. Ibrahim F,
    3. Walker D,
    4. Hassell A,
    5. Choy EH,
    6. Kiely PD,
    7. et al.

    Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol 2012;39:470–5.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Bijlsma JW,
    4. Breedveld FC,
    5. Boumpas D,
    6. Burmester G,
    7. et al.

    Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2011;69:631–7.

    OpenUrl
25. 25.↵
    1. Aletaha D,
    2. Nell VP,
    3. Stamm T,
    4. Uffmann M,
    5. Pflugbeil S,
    6. Machold K,
    7. et al.

    Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.

    OpenUrlCrossRefPubMed